Facility is expected to produce Tysabri for treating multiple sclerosis.

Jacobs Engineering Group won a contract from Biogen Idec to provide engineering, procurement, validation, and site support services for the first cell culture manufacturing facility at the greenfield biotechnology plant in Hillerod, Denmark.

This plant is expected to produce TYSABRI® (natalizumab), which is used in the treatment of multiple sclerosis. The companies expect the facility to be completed in 2009.

Previous articleSartorius and Thermo Fisher Scientific Sign Supply Agreement on TC Tech Products
Next articleAnaptys Biosciences Acquires IP for Antibody Discovery and Protein Optimization